+++ ₿₿ +++ Handeln Sie mit Kryptowährungen mit Hebel - Jetzt mehr erfahren!** +++ ₿₿ +++-w-
11.09.2021 12:12:00

Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?

Pfizer (NYSE: PFE) recently reported positive results for its experimental drug abrocitinib in a late-stage study targeting eczema, an inflammatory skin disease also known as atopic dermatitis. The study featured a head-to-head comparison between Pfizer's drug and Dupixent, which is marketed by Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN).Could Pfizer beat Sanofi and Regeneron in the eczema market? That's the topic of discussion in this Motley Fool Live video recorded on Sept. 1, 2021, with Motley Fool contributors Keith Speights and Brian Orelli.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"